Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

Provided are methods of treating cancer with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with a PI3K (phosphatidylinositol-4,5-bis-phosphate 3-kinase) delta inhibitor.

Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.

Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.

This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.

The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.

Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I:

##STR00001##

wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, and Z.sup.5 independently are nitrogen or carbon; R.sup.1 and R.sup.3 are alkyl; R.sup.2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R.sup.4 is alkyl or hydroxyalkyl.

Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I:

##STR00001##

wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, and Z.sup.5 independently are nitrogen or carbon; R.sup.1 and R.sup.3 are alkyl; R.sup.2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R.sup.4 is alkyl or hydroxyalkyl.

Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I:

##STR00001##

wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z.sup.1, Z.sup.2, Z.sup.3, Z.sup.4, and Z.sup.5 independently are nitrogen or carbon; R.sup.1 and R.sup.3 are alkyl; R.sup.2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R.sup.4 is alkyl or hydroxyalkyl.